3,106 reports of this reaction
2.1% of all DULAGLUTIDE reports
#12 most reported adverse reaction
EXTRA DOSE ADMINISTERED is the #12 most commonly reported adverse reaction for DULAGLUTIDE, manufactured by Eli Lilly and Company. There are 3,106 FDA adverse event reports linking DULAGLUTIDE to EXTRA DOSE ADMINISTERED. This represents approximately 2.1% of all 151,183 adverse event reports for this drug.
Patients taking DULAGLUTIDE who experience extra dose administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EXTRA DOSE ADMINISTERED is a less commonly reported adverse event for DULAGLUTIDE, but still significant enough to appear in the safety profile.
In addition to extra dose administered, the following adverse reactions have been reported for DULAGLUTIDE:
The following drugs have also been linked to extra dose administered in FDA adverse event reports:
EXTRA DOSE ADMINISTERED has been reported as an adverse event in 3,106 FDA reports for DULAGLUTIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EXTRA DOSE ADMINISTERED accounts for approximately 2.1% of all adverse event reports for DULAGLUTIDE, making it a notable side effect.
If you experience extra dose administered while taking DULAGLUTIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.